{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:00:13Z","timestamp":1785391213342,"version":"3.55.0"},"reference-count":71,"publisher":"Bentham Science Publishers Ltd.","issue":"12","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI153031"],"award-info":[{"award-number":["R21AI153031"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21HD109411"],"award-info":[{"award-number":["R21HD109411"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AA030486"],"award-info":[{"award-number":["R01AA030486"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Irinotecan is widely used to treat various types of solid and metastatic cancer. It is an ester prodrug and its hydrolytic metabolite (SN-38) exerts potent anticancer activity. Irinotecan is hydrolyzed primarily by carboxylesterase-2 (CES2), a hydrolase abundantly present in the intestine such as the duodenum. We have identified several potent and covalent CES2 inhibitors such as remdesivir and sofosbuvir. Remdesivir is the first small molecule drug approved for COVID-19, whereas sofosbuvir is a paradigm-shift medicine for hepatitis C viral infection. Irinotecan is generally well-tolerated but associated with severe\/life-threatening diarrhea due to intestinal accumulation of SN-38.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>This study was to test the hypothesis that remdesivir and sofosbuvir protect against irinotecan-induced epithelial injury associated with gastrointestinal toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>To test this hypothesis, formation of organoids derived from mouse duodenal crypts, a robust cellular model for intestinal regeneration, was induced in the presence or absence of irinotecan +\/- pretreatment with a CES2 drug inhibitor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Irinotecan profoundly inhibited the formation of intestinal organoids and the magnitude of the inhibition was greater with female crypts than their male counterparts. Consistently, crypts from female mice had significantly higher hydrolytic activity toward irinotecan. Critically, remdesivir and sofosbuvir both reduced irinotecan hydrolysis and reversed irinotecan-reduced formation of organoids. Human duodenal samples robustly hydrolyzed irinotecan, stable CES2 transfection induced cytotoxicity and the cytotoxicity was reduced by CES2 drug inhibitor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>These findings establish a therapeutic rationale to reduce irinotecan-gastrointestinal injury and serve as a cellular foundation to develop oral formulations of irinotecan with high safety.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389200224666221212143904","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T09:31:47Z","timestamp":1671010307000},"page":"1000-1010","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Covalent CES2 Inhibitors Protect against Reduced Formation of Intestinal Organoids by the Anticancer Drug Irinotecan"],"prefix":"10.2174","volume":"23","author":[{"given":"William","family":"Eades","sequence":"first","affiliation":[{"name":"Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Shen","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanquan","family":"Shi","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0798-5792","authenticated-orcid":true,"given":"Bingfang","family":"Yan","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"Siegel R.L.","year":"2019","unstructured":"Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2019. CA Cancer J Clin 2019,69(1),7-34","journal-title":"CA Cancer J Clin"},{"key":"ref=2","year":"2020","unstructured":"Cancer - statistics"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.21037\/apc-20-29","volume":"3","author":"Suri R.","year":"2020","unstructured":"Suri R.; Zimmerman J.W.; Burkhart R.A.; Modeling human pancreatic ductal adenocarcinoma for translational research: Current options, challenges, and prospective directions. Ann Pancreat Cancer 2020,3,17","journal-title":"Ann Pancreat Cancer"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3892\/ol.2021.12637","volume":"21","author":"Segura-Moreno Y.","year":"2021","unstructured":"Segura-Moreno Y.; Sanabria-Salas M.; Varela R.; Mesa J.; Serrano M.; Decoding the heterogeneous landscape in the development prostate cancer (Review). Oncol Lett 2021,21(5),376","journal-title":"Oncol Lett"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"102062","DOI":"10.1016\/j.scr.2020.102062","volume":"49","author":"Kim J.","year":"2020","unstructured":"Kim J.; Cellular reprogramming to model and study epigenetic alterations in cancer. Stem Cell Res (Amst) 2020,49,102062","journal-title":"Stem Cell Res (Amst)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/GCO.0000000000000671","volume":"33","author":"McCann K.E.","year":"2021","unstructured":"McCann K.E.; Hurvitz S.A.; Innovations in targeted therapies for triple negative breast cancer. Curr Opin Obstet Gynecol 2021,33(1),34-47","journal-title":"Curr Opin Obstet Gynecol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1093\/jnci\/djab131","volume":"113","author":"Islami F.","year":"2021","unstructured":"Islami F.; Ward E.M.; Sung H.; Cronin K.A.; Tangka F.K.L.; Sherman R.L.; Zhao J.; Anderson R.N.; Henley S.J.; Yabroff K.R.; Jemal A.; Benard V.B.; Annual report to the nation on the status of cancer, Part 1: National cancer statistics. J Natl Cancer Inst 2021,113(12),1648-1669","journal-title":"J Natl Cancer Inst"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21637","volume":"70","author":"Miller K.D.","year":"2020","unstructured":"Miller K.D.; Fidler-Benaoudia M.; Keegan T.H.; Hipp H.S.; Jemal A.; Siegel R.L.; Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin 2020,70(6),443-459","journal-title":"CA Cancer J Clin"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"FSO738","DOI":"10.2144\/fsoa-2021-0041","volume":"7","author":"Jones H.","year":"2021","unstructured":"Jones H.; Green V.; England J.; Greenman J.; Current understanding of nonsurgical interventions for refractory differentiated thyroid cancer: A systematic review. Future Sci OA 2021,7(7),FSO738","journal-title":"Future Sci OA"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"e1461","DOI":"10.1002\/cnr2.1461","volume":"5","author":"Schefter A.","year":"2022","unstructured":"Schefter A.; Thomaier L.; Jewett P.; Brown K.; Stenzel A.E.; Blaes A.; Teoh D.; Vogel R.I.; Cross\u2010sectional study of psychosocial well\u2010being among lesbian, gay, bisexual, and heterosexual gynecologic cancer survivors. Cancer Rep 2022,5(2),e1461","journal-title":"Cancer Rep"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1534735420944491","DOI":"10.1177\/1534735420944491","volume":"19","author":"Liu J.","year":"2020","unstructured":"Liu J.; Mao J.J.; Li S.Q.; Lin H.; Preliminary efficacy and safety of Reishi","journal-title":"Integr Cancer Ther"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nrclinonc.2012.99","volume":"9","author":"Cleeland C.S.","year":"2012","unstructured":"Cleeland C.S.; Allen J.D.; Roberts S.A.; Brell J.M.; Giralt S.A.; Khakoo A.Y.; Kirch R.A.; Kwitkowski V.E.; Liao Z.; Skillings J.; Reducing the toxicity of cancer therapy: Recognizing needs, taking action. Nat Rev Clin Oncol 2012,9(8),471-478","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/13548506.2019.1695864","volume":"25","author":"Bellali T.","year":"2020","unstructured":"Bellali T.; Manomenidis G.; Meramveliotaki E.; Minasidou E.; Galanis P.; The impact of anxiety and depression in the quality of life and psychological well-being of Greek hematological cancer patients on chemotherapy. Psychol Health Med 2020,25(2),201-213","journal-title":"Psychol Health Med"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"2040622320970354","DOI":"10.1177\/2040622320970354","volume":"11","author":"O\u2019Reilly M.","year":"2020","unstructured":"O\u2019Reilly M.; Mellotte G.; Ryan B.; O\u2019Connor A.; Gastrointestinal side effects of cancer treatments. Ther Adv Chronic Dis 2020,11,2040622320970354","journal-title":"Ther Adv Chronic Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3389\/fphar.2016.00414","volume":"7","author":"McQuade R.M.","year":"2016","unstructured":"McQuade R.M.; Stojanovska V.; Abalo R.; Bornstein J.C.; Nurgali K.; Chemotherapy-induced constipation and diarrhea: Pathophysiology, current and emerging treatments. Front Pharmacol 2016,7,414","journal-title":"Front Pharmacol"},{"key":"ref=16","first-page":"S391","volume":"24","author":"Natale J.J.","year":"2018","unstructured":"Natale J.J.; Overview of the prevention and management of CINV. Am J Manag Care 2018,24(18)(Suppl.),S391-S397","journal-title":"Am J Manag Care"},{"key":"ref=17","unstructured":"Showing metabocard for SN-38Available from:"},{"key":"ref=18","first-page":"9","volume":"2","author":"Lee G.S.","year":"2019","unstructured":"Lee G.S.; Cody A.S.; Johnson K.C.; Zhao H.; Odelberg S.J.; Li D.Y.; Zhu W.; Estrogen enhances female small intestine epithelial organoid regeneration. J. Bio-X. Res 2019,2,9-15","journal-title":"Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejca.2018.12.034","volume":"110","author":"Ekholm M.","year":"2019","unstructured":"Ekholm M.; Bendahl P.O.; Fern\u00f6 M.; Nordenskj\u00f6ld B.; St\u00e5l O.; Ryd\u00e9n L.; Effects of adjuvant tamoxifen over three decades on breast cancer\u2013free and distant recurrence\u2013free interval among premenopausal women with oestrogen receptor\u2013positive breast cancer randomised in the Swedish SBII:2pre trial. Eur J Cancer 2019,110,53-61","journal-title":"Eur J Cancer"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.3390\/curroncol28030168","volume":"28","author":"Andrahennadi S.","year":"2021","unstructured":"Andrahennadi S.; Sami A.; Manna M.; Pauls M.; Ahmed S.; Current landscape of targeted therapy in hormone receptor-positive and HER2-negative breast cancer. Curr Oncol 2021,28(3),1803-1822","journal-title":"Curr Oncol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1080\/0284186X.2019.1643915","volume":"58","author":"Bens A.","year":"2019","unstructured":"Bens A.; Langballe R.; Bernstein J.L.; Cronin-Fenton D.; Friis S.; Mellemkjaer L.; Preventive drug therapy and contralateral breast cancer: Summary of the evidence of clinical trials and observational studies. Acta Oncol 2019,58(11),1581-1593","journal-title":"Acta Oncol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41571-019-0281-6","volume":"17","author":"Nevala-Plagemann C.","year":"2020","unstructured":"Nevala-Plagemann C.; Hidalgo M.; Garrido-Laguna I.; From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol 2020,17(2),108-123","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/ijc.IJC_507_19","volume":"58","author":"Basade M.","year":"2021","unstructured":"Basade M.; Mane A.; Optimum patient selection for irinotecan-containing regimens in metastatic colorectal cancer: Literature review and lessons from clinical practice. Indian J Cancer 2021,58(1),5-16","journal-title":"Indian J Cancer"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"924","DOI":"10.18632\/oncotarget.27518","volume":"11","author":"Dell\u2019Aquila E.","year":"2020","unstructured":"Dell\u2019Aquila E.; Fulgenzi C.A.M.; Minelli A.; Citarella F.; Stellato M.; Pantano F.; Russano M.; Cursano M.C.; Napolitano A.; Zeppola T.; Vincenzi B.; Tonini G.; Santini D.; Prognostic and predictive factors in pancreatic cancer. Oncotarget 2020,11(10),924-941","journal-title":"Oncotarget"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"104398","DOI":"10.1016\/j.phrs.2019.104398","volume":"148","author":"Bailly C.","year":"2019","unstructured":"Bailly C.; Irinotecan: 25 years of cancer treatment. Pharmacol Res 2019,148,104398","journal-title":"Pharmacol Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00280-018-3720-7","volume":"83","author":"K\u00fcmler I.","year":"2019","unstructured":"K\u00fcmler I.; S\u00f8rensen P.G.; Palshof J.; H\u00f8gdall E.; Skovrider-Ruminski W.; Theile S.; Fullerton A.; Nielsen P.G.; Jensen B.V.; Nielsen D.L.; Oral administration of irinotecan in patients with solid tumors: An open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. Cancer Chemother Pharmacol 2019,83(1),169-178","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00280-019-03819-0","volume":"84","author":"K\u00fcmler I.","year":"2019","unstructured":"K\u00fcmler I.; Eefsen R.L.; S\u00f8rensen P.G.; Theile S.; Fullerton A.; Nielsen P.G.; Jensen B.V.; Nielsen D.L.; An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine. Cancer Chemother Pharmacol 2019,84(2),441-446","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00280-005-0138-9","volume":"58","author":"Pitot H.C.","year":"2006","unstructured":"Pitot H.C.; Adjei A.A.; Reid J.M.; Sloan J.A.; Atherton P.J.; Rubin J.; Alberts S.R.; Duncan B.A.; Denis L.; Schaaf L.J.; Yin D.; Sharma A.; McGovren P.; Miller L.L.; Erlichman C.; A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Cancer Chemother Pharmacol 2006,58(2),165-172","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"7458","DOI":"10.7150\/thno.38081","volume":"9","author":"Han W.","year":"2019","unstructured":"Han W.; Xie B.; Li Y.; Shi L.; Wan J.; Chen X.; Wang H.; Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer. Theranostics 2019,9(24),7458-7473","journal-title":"Theranostics"},{"key":"ref=30","unstructured":"Highlights of prescribing information These highlights do not include all the information needed to use CAMPTOSAR safely and effectively.Available from:"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"19143","DOI":"10.1073\/pnas.1319123110","volume":"110","author":"Chen S.","year":"2013","unstructured":"Chen S.; Yueh M.F.; Bigo C.; Barbier O.; Wang K.; Karin M.; Nguyen N.; Tukey R.H.; Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11). Proc Natl Acad Sci USA 2013,110(47),19143-19148","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1021\/jm9001296","volume":"52","author":"Hicks L.D.","year":"2009","unstructured":"Hicks L.D.; Hyatt J.L.; Stoddard S.; Tsurkan L.; Edwards C.C.; Wadkins R.M.; Potter P.M.; Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity. J Med Chem 2009,52(12),3742-3752","journal-title":"J Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"27958","DOI":"10.18632\/oncotarget.24563","volume":"9","author":"Yu Y.","year":"2018","unstructured":"Yu Y.; Kong R.; Cao H.; Yin Z.; Liu J.; Nan X.; Phan A.T.; Ding T.; Zhao H.; Wong S.T.C.; Two birds, one stone: Hesperetin alleviates chemotherapy-induced diarrhea and potentiates tumor inhibition. Oncotarget 2018,9(46),27958-27973","journal-title":"Oncotarget"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0990","volume":"15","author":"Wardill H.R.","year":"2016","unstructured":"Wardill H.R.; Gibson R.J.; Van Sebille Y.Z.A.; Secombe K.R.; Coller J.K.; White I.A.; Manavis J.; Hutchinson M.R.; Staikopoulos V.; Logan R.M.; Bowen J.M.; Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. Mol Cancer Ther 2016,15(6),1376-1386","journal-title":"Mol Cancer Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.bcp.2012.11.026","volume":"85","author":"Xiao D.","year":"2013","unstructured":"Xiao D.; Shi D.; Yang D.; Barthel B.; Koch T.H.; Yan B.; Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs. Biochem Pharmacol 2013,85(3),439-447","journal-title":"Biochem Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/fcp.12643","volume":"35","author":"Shen Y.","year":"2021","unstructured":"Shen Y.; Eades W.; Yan B.; Remdesivir potently inhibits carboxylesterase\u20102 through covalent modifications: Signifying strong drug\u2010drug interactions. Fundam Clin Pharmacol 2021,35(2),432-434","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jhep.2016.11.025","volume":"66","author":"Shen Y.","year":"2017","unstructured":"Shen Y.; Yan B.; Covalent inhibition of carboxylesterase-2 by the anti-hepatitis C agent sofosbuvir: Implications in organ failures due to hydrolytic interactions with antiretroviral agents. J Hepatol 2017,66,660-661","journal-title":"J Hepatol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.2174\/0929867326666190124121725","volume":"27","author":"Paccosi S.","year":"2020","unstructured":"Paccosi S.; Cresci B.; Pala L.; Rotella C.M.; Parenti A.; Obesity therapy: How and why? Curr Med Chem 2020,27(2),174-186","journal-title":"Curr Med Chem"},{"key":"ref=39","unstructured":"FDA approves first treatment for COVID-19Available from:"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1053\/j.gastro.2016.07.038","volume":"151","author":"Gane E.J.","year":"2016","unstructured":"Gane E.J.; Kowdley K.V.; Pound D.; Stedman C.A.M.; Davis M.; Etzkorn K.; Gordon S.C.; Bernstein D.; Everson G.; Rodriguez-Torres M.; Tsai N.; Khalid O.; Yang J.C.; Lu S.; Dvory-Sobol H.; Stamm L.M.; Brainard D.M.; McHutchison J.G.; Tong M.; Chung R.T.; Beavers K.; Poulos J.E.; Kwo P.Y.; Nguyen M.H.; Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with HCV genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial. Gastroenterology 2016,151(5),902-909","journal-title":"Gastroenterology"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nm.1951","volume":"15","author":"Ootani A.","year":"2009","unstructured":"Ootani A.; Li X.; Sangiorgi E.; Ho Q.T.; Ueno H.; Toda S.; Sugihara H.; Fujimoto K.; Weissman I.L.; Capecchi M.R.; Kuo C.J.; Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche. Nat Med 2009,15(6),701-706","journal-title":"Nat Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1124\/jpet.106.111807","volume":"319","author":"Shi D.","year":"2006","unstructured":"Shi D.; Yang J.; Yang D.; LeCluyse E.L.; Black C.; You L.; Akhlaghi F.; Yan B.; Anti-influenza prodrug oseltamivir is activated by carboxylesterase HCE1 and the activation is inhibited by anti-platelet agent clopidogrel. J Pharmacol Exp Ther 2006,319,1477-1484","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1124\/dmd.122.000918","volume":"50","author":"Shen Y.","year":"2022","unstructured":"Shen Y.; Eades W.; Liu W.; Yan B.; The COVID-19 oral agent molnupiravir is a CES2 substrate: Potential drug-drug interactions and impact of CES2 genetic polymorphism in vitro. Drug Metab Dispos 2022,50(9),1151-1160","journal-title":"Drug Metab Dispos"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1124\/dmd.32.1.35","volume":"32","author":"Song X.","year":"2004","unstructured":"Song X.; Xie M.; Zhang H.; Li Y.; Sachdeva K.; Yan B.; The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes. Drug Metab Dispos 2004,32(1),35-42","journal-title":"Drug Metab Dispos"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1042\/bj20020514","volume":"367","author":"Li Y.","year":"2002","unstructured":"Li Y.; Zhang H.; Xie M.; Hu M.; Ge S.; Yang D.; Wan Y.; Yan B.; DEC1\/STRA13\/ShARP2 is abundantly expressed in colon carcinoma, antagonizes serum deprivation-induced apoptosis and selectively inhibits the activation of procaspases. Biochem J 2002,367,413-422","journal-title":"Biochem J"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.tox.2015.02.007","volume":"330","author":"Chen Y.T.","year":"2015","unstructured":"Chen Y.T.; Trzoss L.; Yang D.; Yan B.; Ontogenic expression of human carboxylesterase-2 and cytochrome P450 3A4 in liver and duodenum: Postnatal surge and organ-dependent regulation. Toxicology 2015,330,55-61","journal-title":"Toxicology"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1042\/BST20210223","volume":"49","author":"Duckworth C.A.","year":"2021","unstructured":"Duckworth C.A.; Identifying key regulators of the intestinal stem cell niche. Biochem Soc Trans 2021,49(5),2163-2176","journal-title":"Biochem Soc Trans"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/ph13110361","volume":"13","author":"Costa D.V.S.","year":"2020","unstructured":"Costa D.V.S.; Costa D.V.S.; Sousa C.N.S.; Silva A.M.H.P.; Medeiros I.S.; Martins D.S.; Martins C.S.; Pequeno A.L.V.; Lima-J\u00fanior R.C.P.; Soares P.M.G.; Vasconcelos S.M.M.; Brito G.A.C.; Souza E.P.; The alpha-lipoic acid improves survival and prevents irinotecan-induced inflammation and intestinal dysmotility in mice. Pharmaceuticals (Basel) 2020,13(11),361","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1124\/dmd.31.1.21","volume":"31","author":"Xie M.","year":"2003","unstructured":"Xie M.; Yang D.; Wu M.; Xue B.; Yan B.; Mouse carboxylesterase M-LK rapidly hydrolyzes antitumor prodrug CPT-11 and the N-terminal three quarter sequence determines substrate selectivity. Drug Metab Dispos 2003,31,21-27","journal-title":"Drug Metab Dispos"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1124\/dmd.105.005587","volume":"33","author":"Kubo T.","year":"2005","unstructured":"Kubo T.; Kim S.R.; Sai K.; Saito Y.; Nakajima T.; Matsumoto K.; Saito H.; Shirao K.; Yamamoto N.; Minami H.; Ohtsu A.; Yoshida T.; Saijo N.; Ohno Y.; Ozawa S.; Sawada J.; Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). Drug Metab Dispos 2005,33(10),1482-1487","journal-title":"Drug Metab Dispos"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1002\/hep4.1736","volume":"5","author":"Shen Y.","year":"2021","unstructured":"Shen Y.; Eades W.; Yan B.; The COVID\u201019 medicine remdesivir is therapeutically activated by carboxylesterase\u20101, and excessive hydrolysis increases cytotoxicity. Hepatol Commun 2021,5(9),1622-1623","journal-title":"Hepatol Commun"},{"key":"ref=52","first-page":"2350","volume":"7","author":"Li F.","year":"2017","unstructured":"Li F.; Jiang T.; Li Q.; Ling X.; Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: Did we miss something in CPT analogue molecular targets for treating human disease such as cancer? Am J Cancer Res 2017,7(12),2350-2394","journal-title":"Am J Cancer Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1111\/cts.13277","volume":"15","author":"Atasilp C.","year":"2022","unstructured":"Atasilp C.; Biswas M.; Jinda P.; Nuntharadthanaphong N.; Rachanakul J.; Hongkaew Y.; Vanwong N.; Saokaew S.; Sukasem C.; Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan\u2010induced toxicity in Asian cancer patients: Meta\u2010analysis. Clin Transl Sci 2022,15(7),1613-1633","journal-title":"Clin Transl Sci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1758834009355164","volume":"2","author":"Stein A.","year":"2010","unstructured":"Stein A.; Voigt W.; Jordan K.; Review: Chemotherapy-induced diarrhea: Pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2010,2(1),51-63","journal-title":"Ther Adv Med Oncol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"114566","DOI":"10.1016\/j.bcp.2021.114566","volume":"190","author":"Wang P.","year":"2021","unstructured":"Wang P.; Jia Y.; Wu R.; Chen Z.; Yan R.; Human gut bacterial \u03b2-glucuronidase inhibition: An emerging approach to manage medication therapy. Biochem Pharmacol 2021,190,114566","journal-title":"Biochem Pharmacol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1038\/s41598-017-03252-4","volume":"7","author":"Chen M.","year":"2017","unstructured":"Chen M.; Cheng K.W.; Chen Y.J.; Wang C.H.; Cheng T.C.; Chang K.C.; Kao A.P.; Chuang K.H.; Real-time imaging of intestinal bacterial \u03b2-glucuronidase activity by hydrolysis of a fluorescent probe. Sci Rep 2017,7(1),3142","journal-title":"Sci Rep"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/bph.14987","volume":"177","author":"Boeing T.","year":"2020","unstructured":"Boeing T.; Souza P.; Speca S.; Somensi L.B.; Mariano L.N.B.; Cury B.J.; Ferreira dos Anjos M.; Quint\u00e3o N.L.M.; Dubuqoy L.; Desreumax P.; Silva L.M.; Andrade S.F.; Luteolin prevents irinotecan\u2010induced intestinal mucositis in mice through antioxidant and anti\u2010inflammatory properties. Br J Pharmacol 2020,177(10),2393-2408","journal-title":"Br J Pharmacol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00280-010-1310-4","volume":"67","author":"Kurita A.","year":"2011","unstructured":"Kurita A.; Kado S.; Matsumoto T.; Asakawa N.; Kaneda N.; Kato I.; Uchida K.; Onoue M.; Yokokura T.; Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of \u03b2-glucuronidase activity in intestinal lumen. Cancer Chemother Pharmacol 2011,67(1),201-213","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1200\/JCO.1993.11.11.2194","volume":"11","author":"Rothenberg M.L.","year":"1993","unstructured":"Rothenberg M.L.; Kuhn J.G.; Burris H.A.; Nelson J.; Eckardt J.R.; Tristan-Morales M.; Hilsenbeck S.G.; Weiss G.R.; Smith L.S.; Rodriguez G.I.; Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993,11(11),2194-2204","journal-title":"J Clin Oncol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1248\/bpb.35.54","volume":"35","author":"Ueno Y.","year":"2012","unstructured":"Ueno Y.; Matsuda H.; Mizutani H.; Iwamoto T.; Okuda M.; Involvement of specific transport system on uptake of lactone form of SN-38 in human intestinal epithelial cell line Caco-2. Biol Pharm Bull 2012,35(1),54-58","journal-title":"Biol Pharm Bull"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ctrv.2008.05.002","volume":"34","author":"Kweekel D.","year":"2008","unstructured":"Kweekel D.; Guchelaar H.J.; Gelderblom H.; Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 2008,34(7),656-669","journal-title":"Cancer Treat Rev"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<786::AIDCNCR5>3.0.CO;2-9","volume":"85","author":"Rothenberg M.L.","year":"1999","unstructured":"Rothenberg M.L.; Cox J.V.; DeVore R.F.; Hainsworth J.D.; Pazdur R.; Rivkin S.E.; Macdonald J.S.; Geyer C.E.; Sandbach J.; Wolf D.L.; Mohrland J.S.; Elfring G.L.; Miller L.L.; Von Hoff D.D.; A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999,85(4),786-795","journal-title":"Cancer"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1200\/JCO.1997.15.8.2910","volume":"15","author":"Pitot H.C.","year":"1997","unstructured":"Pitot H.C.; Wender D.B.; O\u2019Connell M.J.; Schroeder G.; Goldberg R.M.; Rubin J.; Mailliard J.A.; Knost J.A.; Ghosh C.; Kirschling R.J.; Levitt R.; Windschitl H.E.; Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997,15(8),2910-2919","journal-title":"J Clin Oncol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1023\/A:1006456717846","volume":"19","author":"Miya T.","year":"2001","unstructured":"Miya T.; Goya T.; Fujii H.; Ohtsu T.; Itoh K.; Igarashi T.; Minami H.; Sasaki Y.; Factors affecting the pharmacokinetics of CPT-11: The body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. Invest New Drugs 2001,19(1),61-67","journal-title":"Invest New Drugs"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.3390\/cancers14122914","volume":"14","author":"Herrera-G\u00f3mez R.G.","year":"2022","unstructured":"Herrera-G\u00f3mez R.G.; Grecea M.; Gallois C.; Boige V.; Pautier P.; Pistilli B.; Planchard D.; Malka D.; Ducreux M.; Mir O.; Safety and efficacy of bevacizumab in cancer patients with inflammatory bowel disease. Cancers (Basel) 2022,14(12),2914","journal-title":"Cancers (Basel)"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.biocel.2018.11.005","volume":"106","author":"Raslan A.A.","year":"2019","unstructured":"Raslan A.A.; Yoon J.K.; R-spondins: Multi-mode WNT signaling regulators in adult stem cells. Int J Biochem Cell Biol 2019,106,26-34","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jcmgh.2016.06.002","volume":"2","author":"Tsai Y.H.","year":"2016","unstructured":"Tsai Y.H.; Hill D.R.; Kumar N.; Huang S.; Chin A.M.; Dye B.R.; Nagy M.S.; Verzi M.P.; Spence J.R.; LGR4 and LGR5 function redundantly during human endoderm differentiation. Cell Mol Gastroenterol Hepatol 2016,2(5),648-662.e8","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref=68","first-page":"1796","volume":"9","author":"Xie W.","year":"2019","unstructured":"Xie W.; Zhang Y.; Zhang S.; Wang F.; Zhang K.; Huang Y.; Zhou Z.; Huang G.; Wang J.; Oxymatrine enhanced anti-tumor effects of Bevacizumab against triple-negative breast cancer via abating Wnt\/\u03b2-Catenin signaling pathway. Am J Cancer Res 2019,9(8),1796-1814","journal-title":"Am J Cancer Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s10637-020-01052-8","volume":"39","author":"Dai Y.","year":"2021","unstructured":"Dai Y.; Zheng H.; Liu Z.; Wang Y.; Hu W.; The flavonoid luteolin suppresses infantile hemangioma by targeting FZD6 in the Wnt pathway. Invest New Drugs 2021,39(3),775-784","journal-title":"Invest New Drugs"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.neulet.2018.10.063","volume":"692","author":"Shakya R.","year":"2019","unstructured":"Shakya R.; Chongthammakun S.; 17\u03b2-Estradiol attenuates the influence of chronic activated microglia on SH-SY5Y cell proliferation via canonical WNT signaling pathway. Neurosci Lett 2019,692,174-180","journal-title":"Neurosci Lett"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/molehr\/gaw025","volume":"22","author":"Zhang L.","year":"2016","unstructured":"Zhang L.; Xiong W.; Xiong Y.; Liu H.; Liu Y.; 17 \u03b2-Estradiol promotes vascular endothelial growth factor expression via the Wnt\/\u03b2-catenin pathway during the pathogenesis of endometriosis. Mol Hum Reprod 2016,22(7),526-535","journal-title":"Mol Hum Reprod"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389200224666221212143904","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211872\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389200224666221212143904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T10:00:30Z","timestamp":1728554430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211872\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":71,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200224666221212143904","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}